Heart failure & cardiomyopathies
Heart Failure Risk Assessment in Patients with Hypertrophic Cardiomyopathy Based on the H2FPEF Score
Authors' conclusion
The H2FPEF score is independently associated with HF outcome in patients with HCM and may be considered for risk stratification.
Study context
- Population
- Patients with hypertrophic cardiomyopathy (HCM) and preserved LVEF (≥50%)
- Participants
- 955 patients
- Exposure
- Intermediate or high vs low H2FPEF score
- Highn = 105
- Outcome
- Composite of:
- All-cause death
- HF admissions
Methodological detailsmulticentre registry
- Multicentre registry
Main finding
As reported in the abstract
All-cause death or HF admission (multivariate Cox regression)
Each group vs lowHazard ratio (95% CI)P value
Intermediate
2.757(1.612–4.713)
P < 0.001High
3.689(1.908–7.134)
P < 0.001Observational data: associations, not effects.
Secondary outcomes
All-cause death and heart failure (HF) admissions separately
- Died
- 103 (11%)
- First HF hospitalisation
- 57 (6%)
- Event-free survival lower for intermediate and high H2FPEF score
Other independent predictors of primary endpoint
- Female sex, HR
- 1.670 (95% CI 1.157-2.410; p = 0.006)
- Asian ethnicity, HR
- 6.711 (95% CI 4.076-11.048; p < 0.001)
- Ischaemic heart disease, HR
- 1.732 (95% CI 1.133-2.650; p = 0.011)
- Left atrial diameter, HR
- 1.028 (95% CI 1.005-1.051; p = 0.016)
Original publication
Heart Failure Risk Assessment in Patients with Hypertrophic Cardiomyopathy Based on the H2FPEF Score. Eur J Heart Fail. Published 27 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →